Blood Cancer United acquires remaining supply of discontinued investigational drug Luvelta
read at STAT ↗Neutral
Blood Cancer United, a nonprofit focused on blood cancers, is purchasing the remaining inventory of Luvelta, an investigational cancer drug that has been discontinued.
The acquisition aims to preserve the limited supply for patients who may still benefit, despite the drug no longer being under development.
The information was reported in a Pharmalittle newsletter by Ed Silverman on June 12, 2026, which also mentioned other industry topics such as a Novo security breach.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and more”
read at STAT ↗734 words · retrieved Jun 12
comments(0)
5-min edit window · permanent after that